An interventional study of Xylitol chewing gum and Sorbitol chewing gum in Blood Coagulation and Oral Microbiome, sponsored by Bezmialem Vakif University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Bezmialem Vakif University · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Thrombosis with a site in Turkey — 3 open to participants now, 4 under way, none of them phase 3. Thrombosis · Turkey.
Among the 20 studies in Thrombosis with a site in Turkey, this one is the 12th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2026, is one of 8 with no phase, and was the 20th registered.
956 studies on the registry are indexed under Thrombosis; 171 are open to participants now.
Browse Thrombosis studies →3 of the 20 studies in Thrombosis with a site in Turkey are open now. Recruiting first, the newest first:
Konya City Hospital · Sites in Turkey
Ages 18+
Ataturk University · Sites in Turkey
Ages 18–70 · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 127 Thrombosis studies recruiting now, 80 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 35 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 83 across 530 interventional studies indexed under Thrombosis.
Median enrollment 206 across the 14 interventional studies, 1,200 across the 5 observational. Of the 13 that completed or were terminated, 6 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 20 have an industry lead sponsor. The 10 most frequent:
Bezmialem Vakif University is the lead sponsor of 359 studies on the registry; 61 are open to participants now.
Bezmialem Vakif University has 2 studies filed under Thrombosis — fewer than ten, so there is no comparison to draw.
2 of the studies in Thrombosis with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07620119Konya City HospitalMachine Learning for Diagnosis of Occlusive MI in LBBB Patients | 2026-12-31 |
| NCT07951229Bezmialem Vakif UniversityEffect of Xylitol Chewing Gum Consumption on Coagulation Parameters and Salivary Oral Microbiological Markers in Healthy Young Adults | 2027-02-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Thrombosis with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Xylitol is a natural sweetener that is widely used in chewing gum and oral care products because it helps prevent tooth decay. Some recent studies, mostly in older adults with heart disease or other health conditions, have raised questions about whether xylitol may affect blood clotting. It is not known whether regular, everyday amounts of xylitol have any effect on blood clotting in healthy young people.
This study will look at whether chewing xylitol gum every day for 4 weeks changes blood clotting tests in healthy adults aged 18 to 35 years. It will also look at whether xylitol gum changes the bacteria found in saliva.
Sixty healthy volunteers will be randomly assigned to one of two groups of 30 people each. One group will chew gum containing xylitol (2 pieces, 3 times a day, for a total of 6 grams of xylitol per day). The other group will chew gum that contains sorbitol instead of xylitol, in the same way and for the same length of time. Participants and researchers will know which gum is being used.
Blood and saliva samples will be collected at the start of the study and again after 4 weeks. The blood tests will measure platelet count, prothrombin time, activated partial thromboplastin time, fibrinogen, D-dimer, and thrombin-antithrombin complexes. The saliva samples will be used to study the types and amounts of bacteria in the mouth. Researchers will contact participants every week to ask how they are doing and to record any side effects.
Background: Xylitol is a five-carbon sugar alcohol (polyol) that occurs naturally in small amounts in fruits and vegetables. It is widely used as a low-calorie sweetener and, because it helps prevent dental caries, it is commonly added to chewing gum, lozenges and oral care products. In recent years, observational and laboratory studies of some polyol sweeteners, notably erythritol, have suggested links with increased platelet reactivity and thrombotic events. A recent publication reported that high blood levels of xylitol were associated with cardiovascular events in older adults with existing cardiovascular risk factors, and that a single high dose of xylitol (30 g in a drink) increased platelet responsiveness in healthy volunteers over a short period. These findings cannot be directly applied to healthy young adults who use xylitol regularly in everyday amounts, and the effect of repeated daily xylitol intake on blood clotting in this group has not been studied in controlled trials. Xylitol is also known to affect cariogenic bacteria in the mouth, but studies that evaluate systemic clotting markers and the oral microbial profile together are lacking.
Objectives: The primary objective is to evaluate the effect of 4 weeks of daily xylitol chewing gum use on blood coagulation and thrombotic markers in healthy young adults. The secondary objective is to evaluate changes in oral microbiological markers (oral microbiome profile and relative abundance of bacterial species) in saliva.
Study Design: This is a single-center, randomized, open-label, parallel-group, controlled trial conducted at Bezmialem Vakıf University, Faculty of Dentistry, Department of Restorative Dentistry, with blood sampling and laboratory testing performed at the Bezmialem Vakıf University Hospital. Sixty healthy volunteers aged 18 to 35 years are randomly assigned (1:1, computer-based randomization) to a xylitol group (n = 30) or a control group (n = 30). The sample size was calculated using G*Power 3.1 (effect size d = 0.8, alpha = 0.05, power = 0.80), which gave 26 participants per group; 30 per group are enrolled to allow for dropouts. Because the two gums differ in taste and appearance, blinding is not applied.
Intervention: The xylitol group chews gum containing 1 g of xylitol per piece: 2 pieces, 3 times a day, for a total of 6 g of xylitol per day for 4 weeks. The control group chews sorbitol-containing, xylitol-free gum in the same way, with the same frequency and duration. Products are supplied in single-day packs. Participants record their daily gum use in a diary, and use below 80% is defined as non-adherence. During the study, participants must avoid other sweeteners, other chewing gum, polyol-rich products, oral care products that affect the oral flora, probiotics, and nutritional supplements, as well as medicines and herbal products that affect blood clotting.
Study Procedures: At baseline (Day 0), participants receive information, give written informed consent, and are screened by medical history and the eligibility criteria. After an overnight fast of at least 8 hours, a venous blood sample is taken at the hospital laboratory. A saliva sample is collected by a non-invasive method, with participants asked not to eat, drink or chew gum for at least 30 minutes beforehand. Participants then receive their study gum and instructions. Researchers contact participants once a week (telephone, message or in person) to check adherence, concurrent medication and any side effects such as gastrointestinal complaints, allergic reactions, or bleeding- or clotting-related symptoms. At the end of Week 4, blood and saliva sampling is repeated in the same way.
Measurements: Blood: platelet count, prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, D-dimer, and thrombin-antithrombin (TAT) complexes. Saliva: oral microbiome profile and relative abundance of bacterial species. Saliva samples are coded, contain no personal identifiers, and only the microbial content is analyzed; human genome sequences are excluded from analysis.
Statistical Analysis: For each parameter, the change from baseline to Week 4 is calculated and compared between the xylitol and control groups. Normality is tested with the Shapiro-Wilk test. Independent-samples t-test (or Mann-Whitney U test) is used for between-group comparisons, and paired t-test (or Wilcoxon signed-rank test) for within-group comparisons. Repeated-measures ANOVA is used to assess time-by-group interaction where appropriate. Categorical variables are compared with chi-square or Fisher's exact test. Oral microbiome data are summarized by relative abundance and diversity indices (for example, Shannon index), and associations with coagulation markers are examined by correlation analysis. Results are reported with effect sizes and 95% confidence intervals. A two-sided p value below 0.05 is considered statistically significant.
Safety: Xylitol is a food-grade sweetener generally recognized as safe, and the 6 g daily dose is within commonly used consumption levels. Participants are healthy adults with no clotting disorders and no use of anticoagulant or antiplatelet medicines. Participants who develop a serious adverse event, a clinically significant abnormal laboratory result, or a condition requiring prohibited medication are withdrawn and referred for medical care. Participants may leave the study at any time without giving a reason. Personal data are stored under coded identifiers in accordance with Turkish personal data protection law and the Declaration of Helsinki.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants chew xylitol chewing gum (1 g of xylitol per piece), 2 pieces 3 times a day, for a total of 6 g of xylitol per day for 4 weeks.
Dietary Supplement: Xylitol chewing gum
Participants chew xylitol-free, sorbitol-containing chewing gum, 2 pieces 3 times a day, with the same frequency and duration as the xylitol group, for 4 weeks.
Dietary Supplement: Sorbitol chewing gum
Chewing gum containing 1 g of xylitol per piece. Participants chew 2 pieces 3 times a day (6 g of xylitol per day) for 4 weeks.
Xylitol-free chewing gum containing sorbitol. Participants chew 2 pieces 3 times a day for 4 weeks, with the same frequency and duration as the xylitol group.
Change in blood coagulation parameters following xylitol consumption
Changes in platelet count, prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, D-dimer, and thrombin-antithrombin (TAT) complex levels will be evaluated
Time frame: Baseline and Day 30
Change in relative abundance of bacterial species in saliva
Change from baseline to Week 4 in the relative abundance of bacterial species in saliva samples, assessed by oral microbiome analysis
Time frame: Baseline and Day 30
Started Jul 2026 (actual). Primary completion is estimated for Feb 2027, 7 months after the start.
Of 108 non-industry interventional studies with no phase under Thrombosis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 44. This study's planned 7 months is below that.
Counting every sponsor, half of 115 studies reached it within 24 months; a quarter within 9 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.